Expression of Cell Cycle Regulators P21 and P27 as Predictors of Disease Outcome in Colorectal Carcinoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recent studies suggest that aberrations in cell cycle checkpoint controllers are a common feature in human malignancies and predict prognosis independent of stage.
This study correlated two cell cycle regulators (p27 and p21) with clinical and pathological variables in colorectal cancer (CRC) patients to assess their role as prognostic factors.
Patients and Methods
A series of 65 CRC patients were analyzed for p27 and p21 expression in their tumors using immunohistochemistry.
Forty-six percent of tumors showed positive nuclear p27 expression, whereas 72% of cases were completely p21 negative. There were no significant correlations between p27 and p21 expression and gender, age, lymph node involvement, stage, and grade. However, p27 (but not p21) expression revealed highly significant correlation with tumor location (p < 0.01), depth of invasion (p < 0.03), and lympho-vascular invasion (p < 0.02). Tumors with high p27 expression showed a higher recurrence rate than tumors with no expression (p < 0.03). In Kaplan–Meier survival analysis, there was a significant (p = 0.046) difference in disease-free survival (DFS) between p27-positive and p27-negative tumors in favor of the latter. p21 did not show any predictive value of DFS (p < 0.7). Neither p27 nor p21 did predict disease-specific survival (DSS) in Kaplan–Meier analysis, but DSS time was much shorter for p27-positive tumors. In multivariate (Cox) model, p27 lost its value as independent predictor of DFS, and none of the covariates were independent predictors of DSS.
p27 expression seems to be more powerful than p21 expression in providing useful prognostic information in CRC, particularly in predicting the patients at high risk for recurrent disease. Larger cohort and longer follow-up are needed to fully elucidate the value of p27 (and p21) as independent predictors of disease outcome.
- Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25 Suppl 1:S49–56. CrossRef
- Al-Eid H, Arteh S. Cancer incidence report Saudi Arabia. 2005;1–99.
- Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94.
- Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med. 2006;130:318–24.
- Seicean R, Funariu G, Seicean A. Molecular prognostic factors in rectal cancer. Rom J Gastroenterol. 2004;13:223–31.
- Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14:1026–38. CrossRef
- Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699–731. CrossRef
- Buhmeida A, Hilska M, Elzagheid A, Laato M, Collan Y, Syrjanen K, et al. DNA image cytometry predicts disease outcome in stage II colorectal carcinoma. Anticancer Res. 2009;29:99–106.
- Macaluso M, Montanari M, Cinti C, Giordano A. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005;32:452–7. CrossRef
- Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–89. CrossRef
- Chetty R. p27 Protein and cancers of the gastrointestinal tract and liver: an overview. J Clin Gastroenterol. 2003;37:23–7. CrossRef
- Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001;3:91–4. CrossRef
- Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67–74. CrossRef
- Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–75. CrossRef
- Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–7. CrossRef
- Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, Leung DH, et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res. 2002;8:3841–9.
- Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006;99:185–91. CrossRef
- Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998;17:337–44. CrossRef
- Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–5.
- Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996;179:248–53. CrossRef
- Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract. 2001;197:683–9. CrossRef
- Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol. 2000;15:445–53.
- Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000;436:224–8. CrossRef
- Greene F, Page D, Fleming I. AJJC cancer staging manual. 6th ed. New York: Springer; 2002. p. 113–122.
- Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J. 2003;33:119–24. CrossRef
- Wilkinson N, Scott-Conner CE. Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am. 2008;37:253–67. ix. CrossRef
- Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783–99. CrossRef
- Heimann TM, Cohen RD, Szporn A, Gil J. Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991;34:449–54. CrossRef
- Barderas R, Babel I, Casal JI. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl. 2010;4:159–78. CrossRef
- Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010;134:478–90. CrossRef
- Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol. 1999;188:18–23. CrossRef
- Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat. 1998;52:29–41. CrossRef
- Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol. 2001;19:49–52.
- Bendardaf R, Buhmeida A, Ristamaki R, Syrjanen K, Pyrhonen S. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol. 2007;42:1473–8. CrossRef
- Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–88.
- Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol. 2000;95:2953–7. CrossRef
- Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23. CrossRef
- Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–4. CrossRef
- Chen L, Yuan D, Wang GL, Wang Y, Wu YY, Zhu J. Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci. 2010;25:1438–42. CrossRef
- Lim YJ, Kim YH, Ahn GH, Chun HK, Jang WY, Lee JH, et al. Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas. Korean J Gastroenterol. 2004;44:314–20.
- Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, et al. Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol. 2008;97:416–22. CrossRef
- Roa EI, Lantadilla HS, Ibacache SG, de Aretxabala UX. p53 and p27 gene expression in subserosal gallbladder carcinoma. Rev Med Chil. 2009;137:1017–22.
- Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology. 2002;63:180–4. CrossRef
- Kravtsov VG, Shakhmurov MG, Sukmanov OV, Zairat'iants OV, Shirin NI. Expression of cycline-dependent kinase p27 in the low differentiated gastric adenocarcinoma. Arkh Patol. 2006;68:14–6.
- Fan JW, Fan PX, Wang Y, Zhang XQ. Relationship between expression of p27 and DNA ploidy in colorectal carcinoma. Ai Zheng. 2002;21:54–7.
- Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, Schwartz GK, et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol. 2004;11:955–61. CrossRef
- Expression of Cell Cycle Regulators P21 and P27 as Predictors of Disease Outcome in Colorectal Carcinoma
Journal of Gastrointestinal Cancer
Volume 43, Issue 2 , pp 279-287
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Disease outcome
- Adjuvant therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Pathology, King Abdul-Aziz University, P.O. Box 80205, Jeddah, 21589, Saudi Arabia
- 3. Center of Excellence in Genomic Medicine Research, King Abdul-Aziz University, Jeddah, Saudi Arabia
- 2. Department of Medicine, King Abdul-Aziz University, Jeddah, Saudi Arabia
- 4. Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
- 5. Department of Surgery, King Abdul-Aziz University, Jeddah, Saudi Arabia